Sign In
Last checked at 
30 Sep 2020 13:21
Shield Therapeutics plc
("Shield" or the "Group")
Block Listing 6 Monthly Return
Date: 30 September 2020
Name of applicant: | SHIELD THERAPEUTICS PLC
| |||
Name of scheme: | Shield Therapeutics Retention Share Plan | |||
Period of return: | From: | 06 March 2020 | To: | 30 September 2020 |
Balance of unallotted securities under scheme(s) from previous return: | 54,219 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 54,219 | |||
Name of applicant: | SHIELD THERAPEUTICS PLC
| |||
Name of scheme: | Shield Therapeutics plc 2016 Company Share Option Plan | |||
Period of return: | From: | 06 March 2020 | To: | 30 September 2020 |
Balance of unallotted securities under scheme(s) from previous return: | 388,079 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 388,079 | |||
Name of applicant: | SHIELD THERAPEUTICS PLC
| |||
Name of scheme: | The Shield Therapeutics plc 2016 Long Term Incentive Plan | |||
Period of return: | From: | 06 March 2020 | To: | 30 September 2020 |
Balance of unallotted securities under scheme(s) from previous return: | 171,883 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 171,883 | |||
Name of applicant: | SHIELD THERAPEUTICS PLC | |||
Name of scheme: | Shield Therapeutics Retention and Performance Share Plan | |||
Period of return: | From: | 06 March 2020 | To: | 30 September 2020 |
Balance of unallotted securities under scheme(s) from previous return: | 1,885,819 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,885,819 | |||
Name of contact: | Lucy Huntington-Bailey |
Telephone number of contact: | +44 (0) 191 511 8500 |
For further information please contact:
Shield Therapeutics plc | www.shieldtherapeutics.com |
Tim Watts, Chief Executive Officer | +44 (0)20 7186 8500 |
Lucy Huntington-Bailey, General Counsel and Company Secretary | +44 (0) 19 1511 8500 |
|
|
Nominated Advisor and Broker |
|
Peel Hunt LLP |
|
James Steel/Dr Christopher Golden | +44 (0)20 7418 8900 |
Joint Broker finnCap Ltd Geoff Nash/Matt Radley/Alice Lane |
+44 (0)20 7220 0500 |
|
|
Financial PR & IR Advisor |
|
Walbrook PR | +44 (0)20 7933 8780 or shield@walbrookpr.com |
Paul McManus/Lianne Cawthorne | +44 (0)7980 541 893 / +44 (0)7584 391 303 |
About Shield Therapeutics plc
Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
Follow the stocks
